Here, we evaluated the potential of a widely used DPP-4 inhibitor, also known as the gliptin drug class, as a new treatment strategy to mitigate dopamine (DA) neuron dysfunction and loss in PD. This evidence concerns the gene DPP4 and Parkinson disease.